Gossamer Bio Inc Net Income per Employee (GOSS), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Gossamer Bio Inc   (NASDAQ: GOSS)
 

Gossamer Bio Inc Net Income per Employee

GOSS's Quarterly Results, Trends, Rankings, Statistics
Gossamer Bio Inc recorded a cumulative net loss of $-123 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 236 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 3761, from total ranking in previous quarter at 4288.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GOSS Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -762,006 -1,113,556 -1,051,667 -963,957 -856,438
GOSS's Total Ranking # 3761 # 4288 # 3911 # 3983 # 3576
Seq. Net Income Change - - - - -

GOSS Company Profile >> Back to GOSS Efficiency Comparisons >> Compare GOSS Net Income per Employee to its Competitors

GOSS Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 237
Healthcare Sector # 620
Overall Market # 3761

Net Income per Employee Statistics
High Average Low
$ -201,302 $ -1,102,238 $ -1,524,241
(Mar 31 2019)   (Mar 31 2021)




  News about Gossamer Bio Inc Income per employee

Gossamer Bio Pioneering Pathways in Pulmonary Hypertension Treatment and Strategic Talent Development

In the evolving landscape of biotechnology, few players exhibit the potential and strategic foresight seen in Gossamer Bio, Inc. (Nasdaq: GOSS). As a clinical-stage biopharmaceutical entity committed to addressing the unmet medical needs of patients suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), Gossamer Bio recently showcased the depth of its research and developmental triumphs at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress.Held from January 29th to February 1st, 2025, the PVRI Annual Congress serves as a vital forum for researchers and clinicians to exchange insights and update the global medical community on advancements in the understanding and treatment of pulmonary vascular diseases. Gossamer Bio participated prominently, delivering one oral presentation and three poster sessions that highlighted the enduring promise of seralutinib, a drug poised to transform therapeutic approaches within the domain of pulmonary hypertension.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-02T20:53:41+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.